Cannabinol - 20 mg/ml in methanol
CAS: 521-35-7
Ref. 3D-FC19669
5mg | 136,00 € | ||
10mg | 188,00 € | ||
25mg | 352,00 € | ||
50mg | 548,00 € | ||
100mg | 821,00 € |
Información del producto
- 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol3-Amyl-1-hydroxy-6,6 ,9-trimethyl-6H-dibenzo[b,d]pyran6,6,9-Trimethyl-3-pentyl-6H -dibenzo[b ,d]pyran-1-olCBN
- 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
- 6,6,9-Trimethyl-3-Penyl-6H-Dibenzo(B,D)Puran-1-Ol
- 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
- 6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol
- 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl-
- Cannabinol
- NSC 134455
- cannabinol crystalline--dea*schedule I item
Cannabinol is a moderately psychoactive phytocannabinoid that acts as a partial agonist at the CB1 and the CB2 receptors, preferentially binding to the latter (Ki = 1130 nM and 301 nM, respectively) (Yea, 2000). In vitro binding to the CB2 receptor was demonstrated to trigger apoptotic pathways, blocking the release of cytokines in murine T lymphocytes (Munson, 1975). In vivo animal experimental models showed reduction in primary tumor size and an increase in mean survival time upon treatment with cannabinol in Lewis lung adenocarcinoma (Munson, 1975). Cannabinol was also shown to activate peripheral neuronal receptors and promote vasorelaxation, unlike other synthetic cannabinoid receptor agonists, via a CB receptor-independent mechanism.
Propiedades químicas
Consulta técnica sobre: 3D-FC19669 Cannabinol - 20 mg/ml in methanol
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.